Circulation Research, Vol 53, 52-62, Copyright © 1983 by American Heart Association

ARTICLES

Myosin isoenzymes in normal and hypertrophied human ventricular myocardium

JJ Mercadier, P Bouveret, L Gorza, S Schiaffino, WA Clark, R Zak, B Swynghedauw and K Schwartz

We tested the hypothesis that hypertrophy of the human heart is associated with the redistribution of ventricular isomyosins. Human cardiac myosin was isolated from autopsy samples of left ventricular free wall of patients with cardiac hypertrophy and of fetal, young, and adult subjects without heart disease. The following parameters were studied: electrophoretic migration in denaturing and non-denaturing conditions; immunological cross-reactivities with three different types of antibodies; and early phosphate burst size and steady state ATPase activities stimulated by K+-EDTA, Ca++, Mg++, and actin. The antibodies were chosen for their ability to recognize selectively the rat V1 and V3 cardiac isomyosins. The first type was a monoclonal antibody, CCM- 52, prepared against embryonic chick cardiac myosin, the second was an anti-beef atrial myosin, and the third was an anti-rat V1 myosin. CCM- 52 reacted with a greater affinity with rat V3 than with rat V1, and was a probe of mammalian V3. Anti-beef atrial myosin and anti-rat V1 myosin both recognized specifically beef atrial and rat V1 myosins, and were thus considered as probes of mammalian V1. Under non-denaturing conditions, human myosins migrated as rat V3 isomyosin; under denaturing conditions, no difference was observed in any of the electrophoretic parameters between all samples tested, except for the fetal hearts which contained a fetal type of light chain. The immunological studies indicated that human myosins were composed mostly of a V3 type (HV3), but contained also some V1 isomyosin. A technique was developed to quantify the amount of human VI isomyosin which was found to range from almost 0 to 15% of total myosin, and to vary from one heart to the other, regardless of the origin of the heart. Enzymatic studies showed no significant difference between normal, hypertrophied, and fetal hearts in any of the activities tested. However, there was a significant correlation between Ca++-stimulated ATPase activities and HV1 amount (at 0.05 M KCl, n = 18, r2 equal 0.49, P less than 0.01; at 0.5 M KCl, n = 18, r 2 = 0.5, P less than 0.01). These data demonstrate the heterogeneity of human ventricular myosin, which appears to be composed, as in other mammalian species, of V1 and V3 isoforms of different ATPase activities (V1 greater than V3). However it seems that V1 to V3 shifts do not appear to be of physiological significance in the adaptation of human heart to chronic mechanical overloads.

This article has been cited by other articles:

				N. Hamdani, V. Kooij, S. van Dijk, D. Merkus, W. J. Paulus, C. d. Remedios, D. J. Duncker, G. J.M. Stienen, and J. van der Velden Sarcomeric dysfunction in heart failure Cardiovasc Res, March 1, 2008; 77(4): 649 - 658. [Abstract] [Full Text] [PDF]

				C. Woischwill, P. Karczewski, H. Bartsch, H.-P. Luther, M. Kott, H. Haase, and I. Morano Regulation of the human atrial myosin light chain 1 promoter by Ca2+-calmodulin-dependent signaling pathways FASEB J, April 1, 2005; 19(6): 503 - 511. [Abstract] [Full Text] [PDF]

				V. L. M. Rundell, V. Manaves, A. F. Martin, and P. P. de Tombe Impact of {beta}-myosin heavy chain isoform expression on cross-bridge cycling kinetics Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H896 - H903. [Abstract] [Full Text] [PDF]

				D. J Miller, N. G MacFarlane, and G. Wilson Altered oscillatory work by ventricular myofilaments from a rabbit coronary artery ligation model of heart failure Cardiovasc Res, January 1, 2004; 61(1): 94 - 104. [Abstract] [Full Text] [PDF]

				N. R. Alpert, C. Brosseau, A. Federico, M. Krenz, J. Robbins, and D. M. Warshaw Molecular mechanics of mouse cardiac myosin isoforms Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1446 - H1454. [Abstract] [Full Text] [PDF]

				B Swynghedauw and D Charlemagne What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D43 - D49. [Abstract] [PDF]

				P. J. Reiser, M. A. Portman, X.-H. Ning, and C. S. Moravec Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1814 - H1820. [Abstract] [Full Text] [PDF]

				Y. Iwanaga, Y. Kihara, T. Yoneda, T. Aoyama, and S. Sasayama Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction J. Am. Coll. Cardiol., August 1, 2000; 36(2): 635 - 642. [Abstract] [Full Text] [PDF]

				S. Miyata, W. Minobe, M. R. Bristow, and L. A. Leinwand Myosin Heavy Chain Isoform Expression in the Failing and Nonfailing Human Heart Circ. Res., March 3, 2000; 86(4): 386 - 390. [Abstract] [Full Text] [PDF]

				K. A Palmiter, M. J Tyska, D. E Dupuis, N. R Alpert, and D. M Warshaw Kinetic differences at the single molecule level account for the functional diversity of rabbit cardiac myosin isoforms J. Physiol., September 15, 1999; 519(3): 669 - 678. [Abstract] [Full Text] [PDF]

				J van der Velden, L.J Klein, M van der Bijl, M.A.J.M Huybregts, W Stooker, J Witkop, L Eijsman, C.A Visser, F.C Visser, and G.J.M Stienen Isometric tension development and its calcium sensitivity in skinned myocyte-sized preparations from different regions of the human heart Cardiovasc Res, June 1, 1999; 42(3): 706 - 719. [Abstract] [Full Text] [PDF]

				T. Kameyama, Z. Chen, S. P. Bell, P. VanBuren, D. Maughan, and M. M. LeWinter Mechanoenergetic Alterations During the Transition From Cardiac Hypertrophy to Failure in Dahl Salt-Sensitive Rats Circulation, December 22, 1998; 98(25): 2919 - 2929. [Abstract] [Full Text] [PDF]

				T. Ruf, H. Schulte-Baukloh, J. Ludemann, H. Posival, F. Beyersdorf, H. Just, and C. Holubarsch Alterations of cross-bridge kinetics in human atrial and ventricular myocardium Cardiovasc Res, December 1, 1998; 40(3): 580 - 590. [Abstract] [Full Text] [PDF]

				N. S Dhalla, X. Liu, V. Panagia, and N. Takeda Subcellular remodeling and heart dysfunction in chronic diabetes Cardiovasc Res, November 1, 1998; 40(2): 239 - 247. [Abstract] [Full Text] [PDF]

				G. Bonne, L. Carrier, P. Richard, B. Hainque, and K. Schwartz Familial Hypertrophic Cardiomyopathy : From Mutations to Functional Defects Circ. Res., September 21, 1998; 83(6): 580 - 593. [Abstract] [Full Text] [PDF]

				C Mittmann, T Eschenhagen, and H Scholz Cellular and molecular aspects of contractile dysfunction in heart failure Cardiovasc Res, August 1, 1998; 39(2): 267 - 275. [Full Text] [PDF]

				G. Hasenfuss Animal models of human cardiovascular disease, heart failure and hypertrophy Cardiovasc Res, July 1, 1998; 39(1): 60 - 76. [Abstract] [Full Text] [PDF]

				C.P. Clifford and D.J.R. Nunez Human {beta}-myosin heavy chain mRNA prevalence is inversely related to the degree of methylation of regulatory elements Cardiovasc Res, June 1, 1998; 38(3): 736 - 743. [Abstract] [Full Text] [PDF]

				J van der Velden, L.J Klein, M van der Bijl, M.A.J.M Huybregts, W Stooker, J Witkop, L Eijsman, C.A Visser, F.C Visser, and G.J.M Stienen Force production in mechanically isolated cardiac myocytes from human ventricular muscle tissue Cardiovasc Res, May 1, 1998; 38(2): 414 - 423. [Abstract] [Full Text] [PDF]

				J van der Velden, A F M Moorman, and G J M Stienen Age-dependent changes in myosin composition correlate with enhanced economy of contraction in guinea-pig hearts J. Physiol., March 1, 1998; 507(2): 497 - 510. [Abstract] [Full Text] [PDF]

				S. D. Blank, J. A. Lahorra, R. S. McDonald, A. G. Denenberg, J. S. Titus, D. F. Torchiana, W. M. Daggett, and G. A. Geffin Superior Recovery of Hypertrophied Rat Myocardium After Cardioplegic Arrest Ann. Thorac. Surg., February 1, 1998; 65(2): 390 - 396. [Abstract] [Full Text] [PDF]

				P. P de Tombe Altered contractile function in heart failure Cardiovasc Res, February 1, 1998; 37(2): 367 - 380. [Abstract] [Full Text] [PDF]

				G. S. Bodor, A. E. Oakeley, P. D. Allen, D. L. Crimmins, J. H. Ladenson, and P. A. W. Anderson Troponin I Phosphorylation in the Normal and Failing Adult Human Heart Circulation, September 2, 1997; 96(5): 1495 - 1500. [Abstract] [Full Text]

				T.-T. T. Nguyen, E. Hayes, L. A. Mulieri, B. J. Leavitt, H. E.D.J. ter Keurs, N. R. Alpert, and D. M. Warshaw Maximal Actomyosin ATPase Activity and In Vitro Myosin Motility Are Unaltered in Human Mitral Regurgitation Heart Failure Circ. Res., August 1, 1996; 79(2): 222 - 226. [Abstract] [Full Text]

				A.J. Marian and R. Roberts Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy Circulation, September 1, 1995; 92(5): 1336 - 1347. [Full Text]

				R. Yang, S. Bunting, N. Gillett, R. Clark, and H. Jin Growth Hormone Improves Cardiac Performance in Experimental Heart Failure Circulation, July 15, 1995; 92(2): 262 - 267. [Abstract] [Full Text]

				S. Fazio, B. Biondi, G. Lupoli, A. Cittadini, M. Santomauro, A. P. Tommaselli, G. Lombardi, and L. Sacca Evaluation, by Noninvasive Methods, of the Effects of Acute Loss of Thyroid Hormones on the Heart Angiology, April 1, 1992; 43(4): 287 - 293. [Abstract] [PDF]